Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trans-pulmonary Biomarkers in Pulmonary Hypertension

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Vanderbilt University
Gilead Sciences
Information provided by (Responsible Party):
Kenneth Monahan, Vanderbilt University Identifier:
First received: September 19, 2013
Last updated: June 24, 2014
Last verified: June 2014

The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.

Pulmonary Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension [ Time Frame: At baseline ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR) [ Time Frame: At baseline ] [ Designated as safety issue: No ]
  • Vasodilator-induced changes in Pulmonary Hypertension biomarkers [ Time Frame: At baseline ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Differences between Pulmonary Hypertension-related biomarkers in pulmonary circulation and peripheral-venous circulation [ Time Frame: At baseline ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

whole blood

Estimated Enrollment: 100
Study Start Date: August 2013
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Pulmonary Hypertension & WHO group I
Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
Pulmonary Hypertension & WHO group II
Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
Without Pulmonary Hypertension
Participants without Pulmonary Hypertension
Connective Tissue Disease
Participants without PH, but with connective tissue disease

Detailed Description:

Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically indicated right heart catheterization may be enrolled. Clinical data and blood samples will be analyzed.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Pulmonary Vascular Clinic


Inclusion Criteria:

  • Age ≥ 18 years old
  • Undergoing RHC for PH evaluation

Exclusion Criteria:

  • Anemia defined as Hgb < 10 g/dL and HCT < 30
  • Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day of the procedure)
  • Left ventricular ejection fraction ≤ 40%
  • Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on the day of the procedure)
  • IPF, CTEPH, COPD/OSA as the dominant etiology of PH
  • Patient is currently taking PH medication or long-acting nitrates at the time of their RHC.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01961232

Contact: Laura Maynard, RN 615-936-1720

United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Principal Investigator: Kenneth Monahan, MD         
Sponsors and Collaborators
Vanderbilt University
Gilead Sciences
Principal Investigator: Ken Monahan, MD Vanderbilt University
  More Information

Responsible Party: Kenneth Monahan, Assistant Professor, Vanderbilt University Identifier: NCT01961232     History of Changes
Other Study ID Numbers: IRB090650
Study First Received: September 19, 2013
Last Updated: June 24, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
Pulmonary Hypertension
heart disease
lung disease

Additional relevant MeSH terms:
Hypertension, Pulmonary
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases processed this record on November 23, 2014